Bibliografisk note

Funding Information:
We dedicate this work to the memory of Dyanne Søraas, whose courage and willpower continues to inspire us to advance lung cancer diagnostics and treatment. We acknowledge all of the patients who supported our research by consenting access to clinical specimens. We are thankful to Matti Kankainen and Soili Kytölä for advice on the analysis of next-generation sequencing (NGS) and droplet digital PCR (ddPCR) data, Merja Räsänen for processing patient consents, Ashwini Yadav for assistance on KRAS mutation-drug-response association analysis, Astrid Murumägi for reagents and guidance on the establishment of the CR culture protocol, and Vishal Sinha for assistance in drug-response correlation analysis. We thank the Sequencing Core Facility at FIMM, HiLIFE, at the University of Helsinki for NGS analysis, and the Laboratory of Genetics, HUS Diagnostic Center, HUSLAB, at the Helsinki University Hospital for NGS and ddPCR analysis. We thank the HiLIFE Laboratory Animal Centre Core Facility at the University of Helsinki for animal husbandry care and guidance. We thank the thoracic pathologists who helped with the clinical specimen selection, the Laboratory Animal Centre for husbandry support, the FIMM WebMicroscope facility for scanning histological slides, and the FIMM High-Throughput Biomedicine facility for drug screening resources. We thank members of the Verschuren and Wennerberg labs for support and guidance. The study received financial support from the University of Helsinki Integrative Life Science doctoral program (S.S.T.); the Ida Montinin Foundation (S.S.T.); the Väinö and Laina Kivi Foundation (S.S.T.); HUSLAB and the Finnish Medical Foundation (M.I.M.); the Academy of Finland (E.W.V.; grants 307111 and 328473 ); the Novo Nordisk Foundation (K.W.; the Novo Nordisk Foundation Center for Stem Cell Biology, DanStem ; grant no. NNF17CC0027852 ); and a HiPOC 2020 grant from the University of Helsinki (E.W.V.). The Verschuren lab receives funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 859860 and the iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland .

Funding Information:
We dedicate this work to the memory of Dyanne S?raas, whose courage and willpower continues to inspire us to advance lung cancer diagnostics and treatment. We acknowledge all of the patients who supported our research by consenting access to clinical specimens. We are thankful to Matti Kankainen and Soili Kyt?l? for advice on the analysis of next-generation sequencing (NGS) and droplet digital PCR (ddPCR) data, Merja R?s?nen for processing patient consents, Ashwini Yadav for assistance on KRAS mutation-drug-response association analysis, Astrid Murum?gi for reagents and guidance on the establishment of the CR culture protocol, and Vishal Sinha for assistance in drug-response correlation analysis. We thank the Sequencing Core Facility at FIMM, HiLIFE, at the University of Helsinki for NGS analysis, and the Laboratory of Genetics, HUS Diagnostic Center, HUSLAB, at the Helsinki University Hospital for NGS and ddPCR analysis. We thank the HiLIFE Laboratory Animal Centre Core Facility at the University of Helsinki for animal husbandry care and guidance. We thank the thoracic pathologists who helped with the clinical specimen selection, the Laboratory Animal Centre for husbandry support, the FIMM WebMicroscope facility for scanning histological slides, and the FIMM High-Throughput Biomedicine facility for drug screening resources. We thank members of the Verschuren and Wennerberg labs for support and guidance. The study received financial support from the University of Helsinki Integrative Life Science doctoral program (S.S.T.); the Ida Montinin Foundation (S.S.T.); the V?in? and Laina Kivi Foundation (S.S.T.); HUSLAB and the Finnish Medical Foundation (M.I.M.); the Academy of Finland (E.W.V.; grants 307111 and 328473); the Novo Nordisk Foundation (K.W.; the Novo Nordisk Foundation Center for Stem Cell Biology, DanStem; grant no. NNF17CC0027852); and a HiPOC 2020 grant from the University of Helsinki (E.W.V.). The Verschuren lab receives funding from the European Union's Horizon 2020 research and innovation programme under the Marie Sk?odowska-Curie grant agreement no. 859860 and the iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland. S.S.T. K.W. and E.W.V. conceived and designed the study; S.S.T. performed experiments for the development of the FUTC-based drug screening assay; J.B. A.H. and N.L. performed the experiments related to the IHC analysis; S.S.T. S.P. and J.B. performed the data analyses; L.S. advised on the compassionate case study design; S.S.T. E.W.V. and K.W. conducted the data interpretation; J.R. A.K. and M.I.M. assisted in collecting the clinical data and the primary tissue workflow, and received patients? consents; M.I.M. and J.L. performed the clinical pathology analyses; and S.S.T. K.W. and E.W.V. wrote the manuscript. The authors declare no competing interests.

Publisher Copyright:
© 2021 The Author(s)